Bone Biologics (BBLG) Short-Term Debt issuances (2021)
Bone Biologics (BBLG) posted quarterly Short-Term Debt issuances of -$10609.0 for Q1 2021.
Powered by 
Analysis
Bone Biologics (BBLG) Short-Term Debt issuances (2021) Analysis & Trends
Bone Biologics (BBLG) has reported Short-Term Debt issuances for 1 consecutive years, with -$10609.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Short-Term Debt issuances changed N/A year-over-year to -$10609.0; the TTM figure through Dec 2021 stood at -$10609.0 (changed N/A YoY), while the FY2021 annual figure was -$10609.0, down 200.0% from the prior year.
- Short-Term Debt issuances steadied at -$10609.0 in Q1 2021 per BBLG's latest filing.
- Across five years, Short-Term Debt issuances topped out at -$10609.0 in Q1 2021 and bottomed at -$10609.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Issuance (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |